Skip to main content

Publisher: Wiley-Blackwell

Volume 11, Number 5, May 2009

The role of metabolic derangements and glucocorticoid excess in the aetiology of cognitive impairment in type 2 diabetes. Implications for future therapeutic strategies
pp. 407-414(8)
Authors: Strachan, Mark W. J.; Reynolds, Rebecca M.; Frier, Brian M.; Mitchell, Rory J.; Price, Jacqueline F.

Favourites:
ADD

Insulin therapy in type 2 diabetes: what is the evidence?
pp. 415-432(18)
Authors: van Avendonk, Mariëlle J. P.; Rutten, Guy E. H. M

Favourites:
ADD

Treatment of diabetic hypertension
pp. 433-444(12)
Author: Bell, David S. H.

Favourites:
ADD

PROMAXX® inhaled insulin: safe and efficacious administration with a commercially available dry powder inhaler
pp. 455-459(5)
Authors: Heise; Brugger; Cook; Eckers; Hutchcraft; Nosek; Rave; Troeger; Valaitis; White; Heinemann

Favourites:
ADD

Lipohypertrophy: does it matter in daily life? A study using a continuous glucose monitoring system
pp. 460-463(4)
Authors: Overland; Molyneaux; Tewari; Fatouros; Melville; Foote; Wu; Yue

Favourites:
ADD
Favourites:
ADD

Biomarkers of body iron stores and risk of developing type 2 diabetes
pp. 472-479(8)
Authors: Rajpathak; Wylie-Rosett; Gunter; Negassa; Kabat; Rohan; Crandall

Favourites:
ADD

Safety, tolerability, pharmacodynamics and pharmacokinetics of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in healthy subjects
pp. 498-505(8)
Authors: Bush; Matthews; De Boever; Dobbins; Hodge; Walker; Holland; Gutierrez; Stewart

Favourites:
ADD

News and Views
pp. 523-525(3)
Author: Idris, Iskandar

Favourites:
ADD

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
X
Cookie Policy
ingentaconnect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more